Affimed N.V. (Nasdaq:AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today announced the presentation of data updates on two clinical studies at the 15thInternational Conference on Malignant...
Applied Therapeutics Inc. (Nasdaq:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the initiation of a Phase 1/2 study of...
Asieris, a China-based biotech company specializing in the development and commercialization of new drugs for the treatment of genitourinary tumors and related diseases, announced today the completion of enrollment for its APL-1202 Phase Ib trial in the US. This new...
Clinical investigators will study the safety and efficacy of this microvascular device designed to restore blood flow and reduce amputations resulting from below the knee peripheral artery disease Micro Medical Solutions (MMS), an innovator in the field of...
trials targeting PD-L1 and CD16 in patients with solid tumors NantKwest establishes a leading portfolio of off-the-shelf NK cells at clinical stage of development with three engineered NK92 cells in trials: CD16 targeted haNK, CD19/CD16 targeted t-haNK and now...
Email
Text